Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study

Chimeric antigen receptor (CAR) T-cell therapy is a promising option for patients with heavily treated multiple myeloma. Point-of-care manufacturing can increase the availability of these treatments worldwide. We aimed to assess the safety and activity of ARI0002h, a BCMA-targeted CAR T-cell therapy...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The lancet oncology 2023-08, Vol.24 (8), p.913-924
Hauptverfasser: Oliver-Caldés, Aina, González-Calle, Verónica, Cabañas, Valentín, Español-Rego, Marta, Rodríguez-Otero, Paula, Reguera, Juan Luis, López-Corral, Lucía, Martin-Antonio, Beatriz, Zabaleta, Aintzane, Inogés, Susana, Varea, Sara, Rosiñol, Laura, López-Díaz de Cerio, Ascensión, Tovar, Natalia, Jiménez, Raquel, López-Parra, Miriam, Rodríguez-Lobato, Luis Gerardo, Sánchez-Salinas, Andrés, Olesti, Eulàlia, Calvo-Orteu, Maria, Delgado, Julio, Pérez-Simón, José Antonio, Paiva, Bruno, Prósper, Felipe, Sáez-Peñataro, Joaquín, Juan, Manel, Moraleda, José M, Mateos, María-Victoria, Pascal, Mariona, Urbano-Ispizua, Alvaro, Fernández de Larrea, Carlos
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!